82 results about "Vector system" patented technology

Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and / or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.

Systems and methods for reducing latency through motion estimation and compensation techniques are disclosed. The systems and methods include a client device that uses transmitted lookup tables from a remote server to match user input to motion vectors, and tag and sum those motion vectors. When a remote server transmits encoded video frames to the client, the client decodes those video frames and applies the summed motion vectors to the decoded frames to estimate motion in those frames. The server instructs the client to receive input from a user, and use that input to match to cached motion vectors or invalidators. Based on that comparison, the client then applies the matched motion vectors or invalidators to effect motion compensation in a graphic interface. In this manner, latency in video data streams is reduced.

The invention discloses a vector system and method capable of converting mouse embryonic stem cells into embryonic-like cells in a 2-cell period, the vector system comprises a mouse Zfp352 gene sequence, and the nucleotide sequence of the mouse Zfp352 gene is shown as SEQ ID No.1. The invention also discloses a method for converting the mouse embryonic stem cells into embryonic-like cells in a 2-cell period. The invention creatively discovers that through overexpression of the Zfp352 in the mouse embryonic stem cells, the efficiency of converting the mouse pluripotent embryonic stem cells into the totipotent embryonic-like cells in the 2-cell period can be remarkably improved.

Systems and methods for AI-assisted user training and flow query including receiving training including tokenizing the training data with a language learning model into one or more vectors, including a processing vector, and storing the one or more vectors. The systems and methods may receive a request from a user and generate a proficiency score by inputting the request into an adaptive response engine comprising the proficiency vector and proficiency logic and assign the proficiency score to the user. The systems and methods may generate a response associated with the request based on the proficiency score and programed query response logic and output the response.

A system can create a first graph that represents first values of current configurations of a computer hardware as first nodes and first dependencies of the current configurations as first links. The system can create first embedding vectors based on the first graph. The system can input the first embedding vectors to a graph isomorphism network to produce modified first embedding vectors. The system can identify specified configurations for the computer hardware. The system can create a second graph that represents second values of the specified configurations. The system can create second embedding vectors based on the second graph. The system can input the second embedding vectors to the graph isomorphism network to produce modified second embedding vectors. The system can perform a graph isomorphism evaluation on the modified first embedding vectors and the modified second embedding vectors to determine an amount of difference.

This invention belongs to the field of bioengineering technology and discloses a method for specific targeting and scarless simultaneous elimination blue KPC‑2 Gene and IncL plasmid sgRNA sequences, CRISPR / Cas9 vector system and applications. This system targets the sgRNA of the IncL plasmid. blue KPC‑2 The IncL-type plasmid of the gene was designed with an sgRNA that specifically recognizes the conserved sequence at its origin of replication, thus eliminating the drug resistance gene while disrupting the plasmid's replication ability. Conjugation transfer to recipient bacteria significantly improved vector delivery efficiency. An arabinose-inducible promoter was used to control Cas9 gene expression, improving system stability and editing success rate. The vector carries a sucrose-inducible self-eliminating gene, enabling controlled vector self-elimination. This system is not a simple superposition but rather constitutes a time-controlled operational flow: efficient delivery via conjugation, controlled cleavage via induction, and finally, induced self-elimination.

Dual vector systems and these comprehensive mammalian host cells are provided for the expression of multi-chain molecules, with each vector employing a different promoter controlling the expression of a selectable marker. The mammalian host cells can be used to generate a recombinant protein of interest in a mammalian cell culture.

Dual vector systems and mammalian host cells comprising these dual vector systems are provided, wherein each vector employs a different promoter that drives the expression of a selectable marker. A mammalian host cell can be used to produce a recombinant protein of interest in mammalian cell culture.

Systems and methods for operating quantum systems are described. A controller of a quantum system can generate a command signal. The quantum system can include quantum hardware having a plurality of qubits. An interface of the quantum system can control the quantum hardware based on the command signal to sample an input vector represented by the first set of qubits, where the input vector includes mixed states with different Hamming weights. The interface can control the quantum hardware to entangle the first set of qubits to the second set of qubits, where the second set of qubits represent a count of nonzero elements in the input vector. The interface can control the quantum hardware to generate an output vector based on the entanglement of the first set of qubits to the second set of qubits, where the output vector includes one or more states having a specific Hamming weight.

Systems and methods for converting a raster image with a corresponding color scale into a plurality of vectors are provided. An example method includes receiving the raster image and the color scale. In some embodiments, the color scale includes a plurality of colors and a plurality of unit values. In certain embodiments, each color of the plurality of colors corresponds to a unit value of the plurality of unit values. In some embodiments, the raster image includes a plurality of pixels each corresponding to a pixel color. In certain embodiments, each color of the plurality of colors is segmented into a plurality of color channel values. In some embodiments, a model is trained to convert a color to a vector value based on the plurality of segmented color channel values for each color of the plurality of colors and the plurality of unit values. In certain embodiments, the plurality of vectors are generated and each include a vector location, a geometric shape, and a vector value.

The application discloses a Buster transposon system and application thereof, and the system comprises AnBT, CrBT, HvBT, LcBT and LlBT transposons and corresponding transposases, the nucleotide sequences of the AnBT, CrBT, HvBT, LcBT and LlBT transposons are shown in SEQ ID No. 1-5, and the transposases are wild type or enhanced type. The application obtains key elements such as target site repeat (TSD) and terminal inverted repeat (TIR) of the AnBT, CrBT, HvBT, LcBT and LlBT transposons and corresponding transposase sequences through molecular reconstitution, and constructs a set of gene transfer vector systems. The AnBT, CrBT, HvBT, LcBT and LlBT vector systems can effectively mediate gene transfer through cell verification, and have great application potential in transgenic animal preparation and gene therapy.

The application provides a site-specific integration type lentivirus vector system and a preparation method and application thereof, and belongs to the field of genetic engineering; the lentivirus vector system for site-specific integration of AAVS1 safe harbor sites is obtained by integrating a CRISPR / Cas9 system; the lentivirus vector system can guide an exogenous target gene to be precisely and efficiently integrated into an AAVS1 site of a cell genome, thereby effectively avoiding genomic instability caused by random insertion, maintaining the integrity of key physiological functions of the cell, and ensuring long-term, stable and uniform expression of the target gene in the transmission process of daughter cells; the lentivirus vector system provides a safer and more efficient technical solution for the construction of CAR-T, CAR-NK and CAR-M modified immune cells, and has good practicability.

Recombinant polynucleotides encoding fragments of a human dysferlin protein are described herein. In addition, plasmids, viral vectors, dual vector systems, cells, and compositions comprising such recombinant polynucleotides are further described. Such recombinant polynucleotides, plasmids, viral vectors, dual vector systems, cells, and compositions may be used to treat dysferlinopathies. 1004798017 ABSTRACT2023206111 18 Jul 2023 1004798017 ABSTRACT2023206111 18 Jul 2023

This invention relates to constructs, vectors, corresponding host cells, and pharmaceutical compositions that enable effective gene therapy, particularly for genes larger than 5 kb.

Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and / or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.

Polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods for expressing AAV Rep proteins are provided. In certain aspects, among the provided embodiments are polynucleotides, vectors, and systems of vectors or polynucleotides, and cells including the same, that include a polynucleotide that includes a ribozyme. In certain aspects, these polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods may be used to produce higher levels of small Rep transcripts as compared to large Rep transcripts. In certain aspects, these polynucleotides, vector systems, cells, and methods may be used to produce higher levels of small Rep proteins as compared to large Rep proteins. In certain aspects, these polynucleotides, vectors, vector systems, cells, and methods may be used to produce recombinant AAV (rAAV). Increased expression of small Rep as compared to large Rep is useful in many aspects, such as, increasing total virions and increasing packaged virions during the production of rAAV.

Provided herein are systems, methods, and compositions for the modification of target DNA sequences. More particularly, systems, methods, and compositions for cleaving a target DNA in eukaryotic cells with a guide RNA capable of hybridizing with a target sequence and an RNA-guided DNA nuclease are provided. Also provided are vectors and vector systems which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods for identifying and validating novel CRISPR systems.

The present invention features a dual vector system for disrupting and replacing a target gene comprising a mutation (e.g., dominant, recessive mutation). Embodiments of the invention may also provide compositions comprising the dual vector system, and methods of using the dual vector system, including but not limited to methods of modifying the genome of a cell, methods of genomic editing, and methods of treating cells or a subject suffering from a genetic disease comprising a mutation.

The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.

This disclosure provides compositions and methods for treating sensorineural hearing loss and auditory neuropathy, particularly disease forms associated with otomorphin (OTOE) mutations, using OTOE gene therapy. The disclosure provides various compositions comprising a first nucleic acid vector containing a polynucleotide encoding the N-terminal portion of an OTOE isoform 5 protein and a second nucleic acid vector containing a polynucleotide encoding the C-terminal portion of an OTOE isoform 5 protein. These vectors can be used to increase OTOE expression in subjects, such as human subjects with sensorineural hearing loss.

The invention discloses an engineered exosome for expressing a complete antibody and a preparation method of the engineered exosome, and belongs to the field of biotechnology and drug delivery. Aiming at the problem that a complete antibody is difficult to efficiently and stably express on the surface of an exosome membrane in the prior art, the engineering exosome with the complete antibody displayed on the surface is extracted from a culture supernatant after a target antibody and a natural antibody membrane-bound transmembrane region (TMD) sequence are fused, a recombinant lentiviral expression vector is constructed and a host cell is transfected. According to the method, TMD is used as an anchoring element, accurate positioning and efficient expression of an antibody on an exosome membrane are achieved, and the targeting recognition capacity of the exosome and the application potential of the exosome in the fields of targeting delivery, disease treatment and the like are remarkably improved. Experimental results show that the obtained exosome is typical in form, uniform in particle size and high in antibody expression efficiency, and a new technical scheme is provided for a targeting vector system based on the exosome.

The present invention provides an engineered adeno-associated virus AAV capsid, wherein at least one protein on the capsid is modified to comprise an n-mer amino acid sequence insertion or substitution; the amino acid sequence for insertion or substitution is shown as any one of SEQ ID NOS: 6-570 in sequence tables 1-3. Further embodiments provide a vector system comprising one or more vectors encoding an AAV capsid, and a method of delivering a payload to the central nervous system. The methods comprise administering an AAV capsid according to embodiments described herein in vivo or in vitro, and the AAV capsid comprises one or more payload molecules.

The invention relates to a PD1-CD28 chimeric signal conversion receptor and application of the PD1-CD28 chimeric signal conversion receptor in immune cell therapy, and particularly discloses a fusion protein containing a PD-L1 binding region derived from PD1 and a hinge region, a transmembrane region and an intracellular region derived from CD28, homodimers formed by the fusion protein, nucleic acid encoding the fusion protein and a carrier containing the nucleic acid. Also disclosed are immune cells, vector systems, compositions and kits that co-express the fusion proteins and chimeric antigen receptors (CARs), as well as methods of using the immune cells and vector systems to treat diseases in a subject.

The application discloses a kind of construction methods and applications of motor neuron MNX1 reporter cell lines, belong to gene editing and stem cell technical field.The application develops a kind of expression motor neuron MNX1 reporter gene vector system by screening high-activity sgRNA, and vector system includes the guide vector of single-stranded guide RNA targeted to the vicinity of the termination codon of human motor neuron MNX1 gene, and the donor vector carrying the homologous arm in the vicinity of the termination codon of human motor neuron MNX1 gene.The application also includes the construction method of MNX1 reporter gene human pluripotent stem cell line into the above-mentioned vector system, the application can be applied to identify stem cell differentiation source human motor neuron, and the morphology and function of motor neuron are researched under the condition of living cell, provide important platform for the pathogenesis research of muscle-related disease, treatment method evaluation and new treatment target exploration.

The present invention features a dual vector system for disrupting and replacing a target gene comprising a mutation (e.g., dominant, recessive mutation). Embodiments of the invention may also provide compositions comprising the dual vector system, and methods of using the dual vector system, including but not limited to methods of modifying the genome of a cell, methods of genomic editing, and methods of treating cells or a subject suffering from a genetic disease comprising a mutation.

In one aspect, the disclosure relates to recombinant bacterial vectors including a gene encoding at least one antigen from Aeromonas hydrophila or tilapia lake virus, methods of making the same, vaccines incorporating the same, and methods of inducing an immune response in the subject and / or preventing infection by a pathogen in the subject using the same. In one aspect, the subject is a fish in an aquaculture system. In an aspect, the vector or vaccine can be administered by bath immersion or intracoelomic injection and, in some cases, can confer protection against an additional pathogen such as, for example, Edwardsiella piscicida. In any of these aspects, the vectors are susceptible to antibiotics and do not persist in the environment.

The present invention relates to a VSV chimeric vector, characterized in that said vector comprises a gene encoding the glycoprotein GP of the Dandenong virus (DANDV) or the Mopeia virus (MOPV) and lacks a functional gene encoding the envelope protein G of VSV. The present invention also provides a VSV chimeric vector system. Furthermore, the present invention relates to the use of the VSV chimeric vector and system of the present invention, including in medicine, such as in the treatment of solid tumors.

The present invention provides host cells and vector systems that allow precise tuning of expression of selectable marker expression and increased integrated copy number of product genes so that host cell growth and expression of desired proteins or nucleic acid products from the host cell can be optimized.

Novel nucleic acid compositions, vector systems, modified cells, and pharmaceutical compositions that encode or express T cell receptor components directed against melanoma-associated antigen (MAGE) are provided herein. These novel components may be used to enhance an immune response in a subject diagnosed with a MAGE associated disease or condition, such as a hematological malignancy or a solid tumor. Associated methods for treating such subjects are also provided herein.

The present invention provides a dual adeno-associated virus (AAV) vector system for expressing a COL4A3, COL4A4 or COL4A5 polypeptide comprising: (a) a first AAV vector comprising a promoter and a 5' coding sequence (CDS), wherein the 5' CDS encodes an N- terminal part of the COL4A3, COL4A4 or COL4A5 polypeptide; and (b) a second AAV vector comprising a 3' CDS, wherein the 3' CDS encodes a C-terminal part of the COL4A3, COL4A4 or COL4A5 polypeptide. The present invention also provides cells and pharmaceutical compositions comprising said dual AAV vector system and uses thereof, for example for preventing and / or treating Alport Syndrome and related conditions (e.g. any condition in a subject who has a pathogenic variant of a COL4A3, COL4A4 or COL4A5 gene).